Synageva Biopharma Stock Price, News & Analysis (NASDAQ:GEVA)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Synageva Biopharma (NASDAQ:GEVA)

Synageva Biopharma logoSynageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Receive GEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for GEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($6.34)
Net IncomeN/A
Net Margins-6,429.45%
Return on Equity-39.57%
Return on Assets-37.57%


Outstanding SharesN/A

Synageva Biopharma (NASDAQ:GEVA) Frequently Asked Questions

What is Synageva Biopharma's stock symbol?

Synageva Biopharma trades on the NASDAQ under the ticker symbol "GEVA."

How were Synageva Biopharma's earnings last quarter?

Synageva Biopharma Corp (NASDAQ:GEVA) released its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing analysts' consensus estimates of ($1.71) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to analysts' expectations of $1.25 million. Synageva Biopharma had a negative net margin of 6,429.45% and a negative return on equity of 39.57%. View Synageva Biopharma's Earnings History.

Who are some of Synageva Biopharma's key competitors?

Has Synageva Biopharma been receiving favorable news coverage?

Media stories about GEVA stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synageva Biopharma earned a news sentiment score of 0.19 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.91 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Synageva Biopharma?

Shares of GEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Synageva Biopharma?

Synageva Biopharma's mailing address is 33 Hayden Ave, LEXINGTON, MA 02421-7972, United States. The biopharmaceutical company can be reached via phone at +1-781-3579900.

MarketBeat Community Rating for Synageva Biopharma (GEVA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synageva Biopharma (NASDAQ:GEVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Synageva Biopharma (NASDAQ:GEVA) Consensus Price Target History

Price Target History for Synageva Biopharma (NASDAQ:GEVA)

Synageva Biopharma (NASDAQ:GEVA) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016WedbushBoost Price TargetNeutral$67.00 -> $93.00N/AView Rating Details
(Data available from 3/19/2016 forward)


Synageva Biopharma (NASDAQ:GEVA) Earnings History and Estimates Chart

Earnings by Quarter for Synageva Biopharma (NASDAQ:GEVA)

Synageva Biopharma (NASDAQ GEVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/29/2015Q1 2015($1.71)($1.63)$1.14 million$0.93 millionViewN/AView Earnings Details
2/26/2015Q114($1.71)($1.73)$1.25 million$1.24 millionViewListenView Earnings Details
10/30/2014Q3 2014($1.61)($1.46)$1.40 million$1.33 millionViewN/AView Earnings Details
7/30/2014Q2 2014($1.37)($1.52)$1.43 million$2.34 millionViewN/AView Earnings Details
4/30/2014Q1 2014($1.19)($1.16)$1.86 million$1.59 millionViewN/AView Earnings Details
3/3/2014Q4 13($1.02)($1.00)$4.88 million$3.47 millionViewN/AView Earnings Details
10/29/2013Q3 2013($0.90)($1.01)$2.99 million$1.37 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.76)($0.81)$2.90 million$3.41 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.68)($0.54)$2.58 million$5.12 millionViewN/AView Earnings Details
3/11/2013Q4 2012($0.60)($0.62)$2.32 million$2.00 millionViewN/AView Earnings Details
11/6/2012Q3 2012($0.50)($0.43)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.43)($0.45)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.41)($0.35)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.38)($0.65)ViewN/AView Earnings Details
11/14/2011Q3 2011$0.01ViewN/AView Earnings Details
8/12/2011Q2 2011$0.15ViewN/AView Earnings Details
5/13/2011Q1 2011($0.02)ViewN/AView Earnings Details
3/14/2011Q4 2010$0.26ViewN/AView Earnings Details
11/15/2010Q3 2010($0.48)ViewN/AView Earnings Details
8/12/2010Q2 2010$0.30ViewN/AView Earnings Details
5/6/2010Q1 2010$0.22ViewN/AView Earnings Details
3/16/2010Q4 2009$0.39ViewN/AView Earnings Details
11/12/2009Q3 2009$0.45$0.37ViewN/AView Earnings Details
8/13/2009Q2 2009$0.50$0.29ViewN/AView Earnings Details
5/8/2009Q1 2009$0.30$0.50ViewN/AView Earnings Details
3/3/2009Q4 2008$0.45$0.58ViewN/AView Earnings Details
11/6/2008Q3 2008$0.45$0.80ViewN/AView Earnings Details
8/7/2008Q2 2008$0.45$0.53ViewN/AView Earnings Details
5/8/2008Q1 2008$0.45$0.52ViewN/AView Earnings Details
3/13/2008Q4 2007$1.05$1.16ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Synageva Biopharma (NASDAQ:GEVA) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Synageva Biopharma (NASDAQ:GEVA)

No dividend announcements for this company have been tracked by

Insider Trades

Synageva Biopharma (NASDAQ GEVA) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Synageva Biopharma (NASDAQ:GEVA)

Synageva Biopharma (NASDAQ GEVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2015Glen WilliamsSVPSell12,916$214.92$2,775,906.72View SEC Filing  
4/27/2015Anthony QuinnCMOSell10,000$110.00$1,100,000.00View SEC Filing  
4/21/2015Anthony QuinnCMOSell10,000$108.00$1,080,000.00View SEC Filing  
4/15/2015Anthony QuinnCMOSell10,000$105.00$1,050,000.00View SEC Filing  
4/8/2015Glen WilliamsSVPSell42,632$96.08$4,096,082.56View SEC Filing  
4/6/2015Anthony QuinnCMOSell29,503$93.76$2,766,201.28View SEC Filing  
1/7/2015Julian BakerDirectorBuy1,000,000$94.19$94,190,000.00View SEC Filing  
12/29/2014Chris HeberligVPSell6,100$91.14$555,954.00View SEC Filing  
12/17/2014Sanj K PatelCEOSell50,000$88.85$4,442,500.00View SEC Filing  
10/30/2014Carsten BoessCFOSell25,404$80.10$2,034,860.40View SEC Filing  
9/19/2014Mark Alan GoldbergEVPSell790$65.24$51,539.60View SEC Filing  
9/17/2014Mark Alan GoldbergEVPSell13,579$65.03$883,042.37View SEC Filing  
9/2/2014Anthony QuinnCMOSell10,000$70.14$701,400.00View SEC Filing  
6/20/2014Barry D QuartDirectorSell1,375$100.00$137,500.00View SEC Filing  
6/17/2014Barry D QuartDirectorSell1,000$90.00$90,000.00View SEC Filing  
6/12/2014Barry D QuartDirectorSell1,000$83.31$83,310.00View SEC Filing  
6/11/2014Mark Alan GoldbergEVPSell21,597$80.00$1,727,760.00View SEC Filing  
5/16/2014Carsten BoessCFOSell9,927$81.94$813,418.38View SEC Filing  
4/1/2014Anthony QuinnCMOSell20,000$83.53$1,670,600.0015,524View SEC Filing  
3/12/2014Chris HeberligVPSell7,670$98.56$755,955.20192View SEC Filing  
3/6/2014Felix BakerDirectorBuy375,000$105.75$39,656,250.00500View SEC Filing  
1/29/2014Sanj PatelCEOSell102,300$88.12$9,014,676.001,031View SEC Filing  
12/3/2013Mark Alan GoldbergSVPSell7,000$60.52$423,640.00267View SEC Filing  
11/1/2013Mark Alan GoldbergSVPSell7,000$49.96$349,720.00View SEC Filing  
9/25/2013Julian BakerDirectorBuy1,050,000$56.63$59,461,500.00View SEC Filing  
8/21/2013Carsten BoessCFOSell14,481$47.11$682,199.91View SEC Filing  
8/16/2013Carsten BoessCFOSell4,300$47.47$204,121.00View SEC Filing  
7/29/2013Sanj K PatelCEOSell100,000$48.02$4,802,000.00View SEC Filing  
7/16/2013Chris HeberligVPSell2,524$48.43$122,237.32View SEC Filing  
7/11/2013Carsten BoessCFOSell13,237$47.06$622,933.22View SEC Filing  
6/12/2013Sanj K PatelCEOSell70,000$40.65$2,845,500.00View SEC Filing  
2/1/2013Mark Alan GoldbergSVPSell4,417$47.75$210,911.75View SEC Filing  
1/17/2013Anthony QuinnSVPSell5,553$50.07$278,038.71View SEC Filing  
1/16/2013Carsten BoessCFOSell9,927$49.12$487,614.24View SEC Filing  
1/9/2013Thomas J TischDirectorBuy21,039$47.53$999,983.67View SEC Filing  
1/4/2013Julian BakerDirectorBuy859,720$47.53$40,862,491.60View SEC Filing  
9/4/2012Chris HeberligVPSell1,000$49.10$49,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Synageva Biopharma (NASDAQ GEVA) News Headlines

GW Pharma (GWPH) Appoints Catherine Mackey, Alicia Secor and Lord William Waldegrave to BoardGW Pharma (GWPH) Appoints Catherine Mackey, Alicia Secor and Lord William Waldegrave to Board - December 21 at 9:13 AM
Novavax (NVAX) vs. Synageva Biopharma (GEVA) Head to Head ComparisonNovavax (NVAX) vs. Synageva Biopharma (GEVA) Head to Head Comparison - December 18 at 9:34 AM
Syros Pharmaceuticals (SYRS) Names Srinivas Akkaraju to BoardSyros Pharmaceuticals (SYRS) Names Srinivas Akkaraju to Board - June 12 at 6:14 PM
Take Advantage Of Donald Trumps Tweets To Buy Top BiotechsTake Advantage Of Donald Trump's Tweets To Buy Top Biotechs - March 25 at 10:14 AM
Alexion Pharmas Bloated Blockbuster Deal Still HauntsAlexion Pharma's Bloated Blockbuster Deal Still Haunts - February 16 at 5:19 PM
Form 8-K AVEO PHARMACEUTICALS For: Mar 17 - StreetInsider.comForm 8-K AVEO PHARMACEUTICALS For: Mar 17 - - March 22 at 1:18 PM
Opinion: 4 beaten-down Internet companies that are takeover targets - MarketWatchOpinion: 4 beaten-down Internet companies that are takeover targets - MarketWatch - March 17 at 9:37 PM
Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of ... - Business Wire (press release)Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of ... - Business Wire (press release) - March 15 at 7:40 PM
Key Executives for Synageva BioPharma Corp.Key Executives for Synageva BioPharma Corp. - February 18 at 6:13 PM
Synageva Biopharma Corp. Company ProfileSynageva Biopharma Corp. Company Profile - February 18 at 6:13 PM
Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration - Business Wire (press release)Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration - Business Wire (press release) - January 22 at 4:48 PM
FDA Accepts BLA Filing For Synagevas Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA DateFDA Accepts BLA Filing For Synageva's Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date - January 17 at 4:41 PM
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting oSYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting o - June 23 at 8:17 AM

SEC Filings

Synageva Biopharma (NASDAQ:GEVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Synageva Biopharma (NASDAQ:GEVA) Income Statement, Balance Sheet and Cash Flow Statement


Synageva Biopharma (NASDAQ GEVA) Stock Chart for Monday, March, 19, 2018

Loading chart…

This page was last updated on 3/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.